Autolus Therapeutics Reports Q3 Revenue Beat and Upward 2026 Product Guidance
Autolus Therapeutics (AUTL) reported third-quarter financial results featuring a significant year-over-year revenue increase of 95.1%, reaching $41.24 million. While the company missed GAAP earnings per share expectations with a loss of $0.21, the top-line performance exceeded analyst estimates by $1.21 million. Looking ahead, management provided optimistic guidance for its product AUCATZYL, projecting full-year 2026 net product revenue to meet or exceed the upper end of the $150 million range. This forward-looking guidance suggests strong confidence in the commercial trajectory of their therapeutic pipeline.
Tickers: $AUTL
Topics: biotechnology earnings miss financial guidance revenue beat
Read the full article at Seeking Alpha
Part of the story Blackbaud Stock Rises Nearly 30% Driven by AI Product Launches and Strong Q3 Earnings (3 articles)